JPRN-UMIN000002771已完成1 期
Phase I clinical trial of Wilms tumor 1 peptide vaccination for patients with advanced cancer - Phase I clinical trial of Wilms tumor 1 peptide vaccination
Tokyo Women's Medical University0 个研究点目标入组 18 人开始时间: 2009年11月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Pregnant female Patient with severe underlying disease Patient with severe allergy disease
研究者
相似试验
已完成
1 期
Phase I/II clinical trial of WT1 peptide-based vaccine for the patients with malignant tumors.Malignant solid tumors, Malignant lymphoma, Multiple Myeloma, Acute leukemiaJPRN-UMIN000002001Department of Cancer immunotherapy, Osaka University Graduate School of Medicine30
已完成
不适用
Phase II clinical trial of WT1 peptide-based vaccine combined with Temozoromide for patients with glioblastoma.GlioblastomaJPRN-UMIN000026965Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine35
尚未招募
1 期
Phase II clinical trial of WT1 peptide-based vaccine for pediatric patients with recurrent malignant gliomaMalignant Glioma DIPGJPRN-UMIN000013258Osaka university graduate school of medicine18
尚未招募
1 期
Phase I study of Wilms' tumor gene WT1 peptide vaccination combined with gemcitabine for patients with advanced non-small-cell lung canceradvanced or recurrent non-small-cell lung cancerJPRN-UMIN000005226School of Medicine, Keio University10
已完成
1 期
Phase I study of Wilms' tumor gene WT1 peptide pulsed dendritic cell vaccination combined with docetaxel for patients with advanced or recurrent esophageal cancerAdvanced or recurrent esophageal cancerJPRN-UMIN000006704School of Medicine, Keio University10